Business · Companies · 3 hrs ago
Mesoblast reports higher Ryoncil revenue and lower cash spending
Mesoblast reported higher Ryoncil sales in its first fiscal quarter.
Revenue from the treatment rose 44% to US$28 million.
Net operating cash spend fell 85% to US$2.3 million, compared with US$14.9 million in the prior period.
Ryoncil is the first and only FDA-approved mesenchymal stromal cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease.
Adoption grew across 54 treatment sites, and the company recorded a high number of new patient starts in September after a seasonal slowdown in July and August.
Mesoblast had US$99 million in cash on 30 September 2026, and the figures are preliminary and subject to audit.
The company plans to expand Ryoncil use among eligible hospitals and clinics while advancing other treatments and overseas partnerships.
Mesoblast reported that Ryoncil net revenue rose 44% to US$28 million in the first fiscal quarter.
Net operating cash spend fell 85% to US$2.3 million.
The company had US$99 million in cash at 30 September 2026.
Mesoblast said September saw record new patient starts after a seasonal slowdown in July and August.
The results are preliminary and subject to audit.
- Who
- Mesoblast Ltd, which sells Ryoncil.
- What
- The company reported higher Ryoncil revenue and lower net operating cash spend in the first fiscal quarter.
- When
- The results were reported on 15 October 2026. The cash balance was as of 30 September 2026.
- Where
- Not stated
- Why
- Mesoblast attributed the growth and improved cash position to greater Ryoncil adoption across 54 onboarded treatment sites.
This story does not have two clearly opposing sides.
Mesoblast said new patient starts slowed seasonally during these months.
Mesoblast reported record new patient starts.
The company reported a cash balance of US$99 million.
Mesoblast reported its first-quarter results.
- Ryoncil net revenue
- US$28 million, up 44%
- Net operating cash spend
- US$2.3 million, down 85%
- Cash balance
- US$99 million at 30 September 2026
- Onboarded treatment sites
- 54
- New patient starts
- Record level in September